Developer docs
API playgroundTry for free, no card

Search company profiles

pixlbio (formerly DefiniGEN)

Full company profile

uuid0002bff

Namestring
pixlbio (formerly DefiniGEN)
Legal namestring
Pixl Bio AB
Websiteurl
pixl.bio
Company typeenum
Private
Founded yearint
2012
Descriptiontext

pixlbio (formerly DefiniGEN) is a privately held preclinical biology platform company that combines human iPSC-derived cell models with AI-driven high-content phenomics to support drug discovery and safety assessment for pharmaceutical and biotechnology customers. Founded in 2012 in Cambridge, UK and reincorporated in Uppsala, Sweden following the July 2025 merger of DefiniGEN and Phenaros, the company offers a unified portfolio comprising pixCells (iPSC-derived hepatocytes, hepatic stellate cells, and intestinal organoids), pixCellPaint (automated Cell Painting and microscopy), and pixCellServices (end-to-end custom studies with AI analytics). Its proprietary differentiation protocols generate primary-like hepatocytes with validated CYP450 activity, albumin secretion, and stable function for 30+ days in culture, while its phenomics platform applies vision foundation models (DINOv3) and custom Cellpose-SAM segmentation to convert cellular imagery into structured phenotypic fingerprints for mechanism-of-action classification, toxicity prediction, and disease phenotype characterization.

The company monetizes through a hybrid model: catalog unit pricing for cryopreserved iPSC cell products (£1,500–£2,800 per vial across wild-type and disease models) and quote-based fees for custom studies, CRISPR gene editing services, and end-to-end research engagements. It serves a horizontal customer base anchored by pharmaceutical companies (named customers include AstraZeneca, Sanofi, and Deep Genomics) with the company claiming adoption by 11 of the top 20 global pharmaceutical companies. Go-to-market is direct enterprise field sales supported by scientific content marketing, industry conference participation (ELRIG, Society of Toxicology, FIMM), and a recently launched SaaS platform with API-based experiment tracking and in-silico phenomic predictions. Strategic positioning is reinforced by participation in the FDA-3Rs Collaborative cross-platform DILI study, with the project's Letter of Intent accepted into the FDA ISTAND qualification program in January 2026, positioning pixlbio as one of eight selected commercial liver MPS developers in this landmark regulatory science initiative.

Short descriptiontext

pixlbio combines human iPSC-derived cell models (hepatocytes, stellate cells, intestinal organoids) with AI-driven high-content phenomics to deliver predictive preclinical data for drug discovery and safety assessment, serving pharmaceutical and biotechnology customers including AstraZeneca, Sanofi, and Deep Genomics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUppsala, Sweden
HQ citystring
Uppsala
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iPSC cell models, drug discovery services, phenomics platform, disease modeling, hepatocyte models
Industry5 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1iPSC-derived Cell Products
TypeOne Time License
Description

Sale of cryopreserved iPSC-derived hepatocytes, stellate cells, and intestinal organoids. Products available as wild-type, disease-specific, or CRISPR-edited formats. Revenue generated from unit sales of cell products at catalog prices.

pixl.bio
2pixCellServices - Custom Studies & Analytics
TypeProfessional Services
Description

End-to-end research services including study design, experimental execution, AI analytics, and delivery of structured data packages with interpretation. From target validation to toxicology and mechanism-of-action studies.

pixl.bio
3pixCellPaint - Phenomics Services
TypeProfessional Services
Description

Cell painting and high-content phenomics services providing morphological profiling data for customer cell models or pixlbio's own iPSC-derived systems.

pixl.bio
4CRISPR Gene Editing Services
TypeProfessional Services
Description

Custom CRISPR-Cas9 gene editing services for creating disease models from customer iPSC lines or pixlbio's validated lines. Includes cell line evaluation, sgRNA design, transfection, clone screening, and final validation.

pixl.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details7 tiers
1pixHep wild-type iPSC-derived hepatocytes
ModelUnit PricingBilling cadencePay-as-you-go
Notes

pixHep-003 iPSC-derived Hepatocyte Donor 1, Male (Wild Type): £1,700 per cryopreserved vial (1 x 10^6 viable cells). Also available from Donors 2 and 3.

pixl.bio
2pixHep A1ATD disease models
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Patient-derived PiZZ (HEP-001), CRISPR-engineered homozygous PiZZ (HEP-003-AAT-z), and CRISPR-engineered heterozygous PiMZ (HEP-003-AAT-a): £2,500 per cryopreserved vial.

pixl.bio
3pixHep UCD disease models
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CRISPR-engineered OTC D175V (HEP-003-OTC-a) and ASS1 G390R (HEP-003-ASS1-a): £2,500 per cryopreserved vial.

pixl.bio
4pixStellate iPSC-derived stellate cells
ModelUnit PricingBilling cadencePay-as-you-go
Notes

pixHSC-003 iPSC-derived Stellate Cells Donor 1, Male: £1,500 per cryopreserved vial (1 x 10^6 viable cells).

pixl.bio
5pixIO intestinal organoids
ModelUnit PricingBilling cadencePay-as-you-go
Notes

pixIO-INT-003 iPSC-derived Human Intestinal Organoids (Wild-Type): £2,800 per cryopreserved vial containing 250 organoids.

pixl.bio
6pixHep/pixStellate Co-Culture Models
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Co-culture system combining pixHep (HEP-003) and pixStellate (HSC-003): £1,700 for hepatocyte vial + £1,500 for stellate vial. Requires one cryopreserved vial of each.

pixl.bio
7MASLD CRISPR disease models
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CRISPR-engineered TM6SF2 E167K (HEP-003-TM6SF2-a) and PNPLA3 I148M (HEP-003-PNPLA3-h): pricing not explicitly stated for these variants.

pixl.bio
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1pixCells
Description

Human iPSC-derived cell models including hepatocytes, stellates, and organoids engineered for physiological relevance, scalability, and stability.

pixl.bio
+5 more records
Core offering1 text field

pixlbio develops and commercializes human induced pluripotent stem cell (iPSC)-derived cell models and an AI-driven phenomics platform for drug discovery, disease modeling, and preclinical safety assessment. The company sells cryopreserved hepatocytes (pixHep), hepatic stellate cells (pixStellate), intestinal organoids (pixIO), and disease-specific liver models (MASLD, A1ATD, PFIC2, UCD), alongside the pixCellPaint high-content assay, the pixlbio AI Phenomics Platform, and end-to-end pixCellServices contract research.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to ~69% balanced accuracy in leave-one-out compound identification for DILI prediction
+3 more records
Product overview1 text field

pixlbio is a unified platform combining human iPSC-derived cell models (pixCells portfolio) with AI-driven phenomics for predictive drug discovery and safety assessment. The platform integrates three core product lines: pixHep (iPSC-derived hepatocytes), pixStellate (hepatic stellate cells), and pixIO (intestinal organoids) as the biological foundation; pixCellPaint for high-content cell painting and automated imaging; and pixCellServices for end-to-end research studies with AI analytics. pixCellPaint captures morphological fingerprints via Cell Painting, which pixlbio's AI models analyze to generate predictive insights for drug response, toxicity, and mechanism of action. The SaaS platform delivers structured data, dashboards, and consultative insights. Disease-specific models include MASLD, A1ATD, PFIC2, and UCD variants, alongside custom CRISPR-engineered models. The company was formed in July 2025 through the merger of DefiniGEN (iPSC expertise) and Phenaros (AI phenomics), headquartered in Uppsala, Sweden.

Product and service12 records
1pixHep
CategoryiPSC Cell Models
Description

Human induced pluripotent stem cell (iPSC)-derived hepatocytes supplied as cryopreserved, single-donor cells for drug discovery, hepatotoxicity testing, and liver disease research, sold to pharmaceutical and biotechnology R&D customers.

2pixStellate
CategoryiPSC Cell Models
Description

Human iPSC-derived hepatic stellate cells for in vitro modeling of liver fibrosis and stellate cell biology, used in combination with pixHep in fibrosis and co-culture applications.

3pixIO
CategoryiPSC Organoid Models
Description

Human iPSC-derived intestinal organoids for gastrointestinal disease modeling, gut-toxicity testing, and pharmacology research, sold to pharma and biotech discovery teams.

4pixCellPaint
CategoryPhenotypic Assay Platform
Description

High-content cell painting phenomics assay that produces multi-parameter morphological readouts from pixlbio's iPSC-derived cells, enabling quantitative phenotypic profiling for compound screening and target validation.

5pixCellServices
CategoryContract Research Services
Description

End-to-end drug discovery and disease modeling research services in which pixlbio executes custom iPSC-derived model generation, assay design, pixCellPaint phenotypic screening, and AI-driven data analysis on behalf of pharma, biotech, and academic clients.

6pixlbio AI Phenomics Platform
CategoryAI Phenomics Software
Description

AI and machine learning platform that analyzes high-content imaging data from pixCellPaint and customer assays, extracting quantitative morphological features and supporting target identification, hit triage, and mechanism-of-action studies.

7Custom iPSC Disease Models
CategoryCustom Cell Model Service
Description

Bespoke iPSC-derived disease models engineered to customer-specified genotypes or indications, including custom gene edits and customer-driven donor backgrounds for proprietary research programs.

8pixHep MASLD Model
CategoryDisease-Specific Liver Models
Description

Disease-specific iPSC-derived hepatocyte model for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NASH/NAFLD), used to study hepatic steatosis, inflammation, and fibrosis in a human-relevant in vitro setting.

9pixHep A1ATD Model
CategoryDisease-Specific Liver Models
Description

Disease-specific iPSC-derived hepatocyte model carrying Alpha-1 antitrypsin deficiency (A1ATD) genotype, enabling study of misfolded protein accumulation and liver pathology in A1ATD drug discovery.

10pixHep PFIC2 Model
CategoryDisease-Specific Liver Models
Description

Disease-specific iPSC-derived hepatocyte model for progressive familial intrahepatic cholestasis type 2 (PFIC2), used to model BSEP transporter dysfunction and cholestasis in vitro for rare liver disease drug discovery.

11pixHep UCD Model
CategoryDisease-Specific Liver Models
Description

Disease-specific iPSC-derived hepatocyte model for urea cycle disorders (UCD), used to study ammonia detoxification defects and OTC/ASS1/CPS1 pathway dysfunction in vitro.

12pixHep / pixStellate Co-Culture
CategoryCo-Culture Disease Models
Description

Co-culture system combining pixHep hepatocytes with pixStellate cells to model hepatocyte-stellate cell cross-talk in liver fibrosis and inflammation studies, sold as an integrated disease modeling product.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership8 partners
1FDA-CDER
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

FDA Center for Drug Evaluation and Research (CDER) co-leads the landmark cross-platform DILI study with the 3Rs Collaborative. Pixl Bio (operating as DefiniGEN at study initiation) was one of eight selected commercial liver MPS platforms contributing to the FDA ISTAND qualification program. Project Letter of Intent accepted into ISTAND in January 2026.

pixl.bio
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

3Rs Collaborative handles project coordination and dissemination for the landmark cross-platform DILI study co-led with FDA-CDER. Pixl Bio is a member of the Microphysiological Systems initiative.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

NIH National Institute of Environmental Health Sciences/NICEATM provides independent data governance including compound selection, blinding, and statistical analysis for the cross-platform DILI study.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Contributes context of use and qualification expertise to the FDA-3Rs Collaborative cross-platform DILI study supporting regulatory qualification of liver MPS technologies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AstraZeneca is a major pharmaceutical customer and represented on the technical leadership committee for the cross-platform DILI study. Also serves as host for the ELRIG Cell-based Screening 2026 conference at their R&D site in Gothenburg.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Sanofi selected pixlbio as recipient of the iDEA-TECH Awards Program recognizing their high-quality predictive models and expertise in Cell Painting, AI and predictive modelling.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Provides technical leadership and compound selection guidance for the FDA-3Rs Collaborative cross-platform DILI study consortium.

Strategic tierFlagshipTypeOthers
Description

In July 2025, DefiniGEN was acquired by Phenaros, forming pixlbio. Phenaros brought complementary capabilities in high-throughput Cell Painting phenomics, AI-driven image analysis, and predictive modeling from their Uppsala founding team.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

InSphero provides 3D microtissue and organoid-based assays including liver models for toxicity and disease research, competing directly with pixlbio's pixHep and pixIO products in pharma drug safety and metabolic disease applications.

TypeDirect peer
Description

REPROCELL provides upcyte hepatocytes and iPSC-derived hepatic cells for drug metabolism and toxicology, directly comparable to pixlbio's pixHep cell product line in addressing pharma needs for human-relevant liver models.

TypeDirect peer
Description

Emulate's Liver-Chip is a leading organ-on-chip platform using primary or iPSC-derived hepatocytes under controlled flow conditions for DILI and drug safety assessment. Direct competitor to pixlbio's pixHep-based offering and fellow FDA-3Rs study participant.

TypeDirect peer
Description

MIMETAS develops organ-on-chip platforms including liver models under the OrganoPlate brand, providing competing MPS solutions to pixlbio for DILI, metabolism, and disease modeling in pharma preclinical pipelines.

TypeBroad incumbent
Description

Lonza manufactures primary and iPSC-derived hepatocytes at industrial scale and offers cell therapy and discovery services, providing a broad-incumbent alternative for pharma customers evaluating pixlbio's pixHep cell products.

TypeEmerging player
Description

Organovo focuses on 3D bioprinted human tissues including liver tissue for preclinical research, an emerging alternative to iPSC-derived hepatocyte models like pixHep with partially overlapping pharma use cases.

7CN Bio
TypeDirect peer
Description

CN Bio's PhysioMimix liver MPS platform offers single- and multi-organ microphysiological systems for DILI and ADME studies, directly competing with pixlbio in iPSC-derived liver models for pharma preclinical workflows. Both companies participate in the FDA-3Rs Collaborative cross-platform DILI study.

TypeBroad incumbent
Description

Thermo Fisher offers Gibco primary hepatocytes, iPSC-derived cell products, and high-content imaging instruments that overlap with pixlbio's pixCells and pixCellPaint offerings, representing a broad life-science tools incumbent.

TypeDirect peer
Description

Cyprotex offers preclinical DILI and ADME services including iPSC-derived hepatocyte assays, overlapping with pixlbio's pixCellServices for pharma customers. As part of Evotec, it represents a larger integrated CRO competitor.

TypeBroad incumbent
Description

As a top-5 pharma with substantial internal iPSC, organoid, and high-content screening capabilities, Roche represents a broad incumbent that could either be a major pixlbio customer or a long-term competitor through internalization of similar capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

pixlbio (formerly DefiniGEN)

Drug Discovery Servicespixl.bio

pixlbio combines human iPSC-derived cell models (hepatocytes, stellate cells, intestinal organoids) with AI-driven high-content phenomics to deliver predictive preclinical data for drug discovery and safety assessment, serving pharmaceutical and biotechnology customers including AstraZeneca, Sanofi, and Deep Genomics.

What pixlbio (formerly DefiniGEN) does

pixlbio (formerly DefiniGEN) is a privately held preclinical biology platform company that combines human iPSC-derived cell models with AI-driven high-content phenomics to support drug discovery and safety assessment for pharmaceutical and biotechnology customers. Founded in 2012 in Cambridge, UK and reincorporated in Uppsala, Sweden following the July 2025 merger of DefiniGEN and Phenaros, the company offers a unified portfolio comprising pixCells (iPSC-derived hepatocytes, hepatic stellate cells, and intestinal organoids), pixCellPaint (automated Cell Painting and microscopy), and pixCellServices (end-to-end custom studies with AI analytics). Its proprietary differentiation protocols generate primary-like hepatocytes with validated CYP450 activity, albumin secretion, and stable function for 30+ days in culture, while its phenomics platform applies vision foundation models (DINOv3) and custom Cellpose-SAM segmentation to convert cellular imagery into structured phenotypic fingerprints for mechanism-of-action classification, toxicity prediction, and disease phenotype characterization.

The company monetizes through a hybrid model: catalog unit pricing for cryopreserved iPSC cell products (£1,500–£2,800 per vial across wild-type and disease models) and quote-based fees for custom studies, CRISPR gene editing services, and end-to-end research engagements. It serves a horizontal customer base anchored by pharmaceutical companies (named customers include AstraZeneca, Sanofi, and Deep Genomics) with the company claiming adoption by 11 of the top 20 global pharmaceutical companies. Go-to-market is direct enterprise field sales supported by scientific content marketing, industry conference participation (ELRIG, Society of Toxicology, FIMM), and a recently launched SaaS platform with API-based experiment tracking and in-silico phenomic predictions. Strategic positioning is reinforced by participation in the FDA-3Rs Collaborative cross-platform DILI study, with the project's Letter of Intent accepted into the FDA ISTAND qualification program in January 2026, positioning pixlbio as one of eight selected commercial liver MPS developers in this landmark regulatory science initiative.

pixlbio (formerly DefiniGEN) firmographics

Firmographics
Name
pixlbio (formerly DefiniGEN)
Legal name
Pixl Bio AB
Website
https://pixl.bio
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
pixlbio combines human iPSC-derived cell models (hepatocytes, stellate cells, intestinal organoids) with AI-driven high-content phenomics to deliver predictive preclinical data for drug discovery and safety assessment, serving pharmaceutical and biotechnology customers including AstraZeneca, Sanofi, and Deep Genomics.
Ownership category
akta.pro rank

pixlbio (formerly DefiniGEN) industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • IPSC cell models
  • Drug discovery services
  • Phenomics platform
  • Disease modeling
  • Hepatocyte models

Where pixlbio (formerly DefiniGEN) is headquartered

Location

Headquarters

HQ city
Uppsala
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

pixlbio (formerly DefiniGEN) business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. iPSC-derived Cell Products: Sale of cryopreserved iPSC-derived hepatocytes, stellate cells, and intestinal organoids. Products available as wild-type, disease-specific, or CRISPR-edited formats. Revenue generated from unit sales of cell products at catalog prices.
  2. pixCellServices - Custom Studies & Analytics: End-to-end research services including study design, experimental execution, AI analytics, and delivery of structured data packages with interpretation. From target validation to toxicology and mechanism-of-action studies.
  3. pixCellPaint - Phenomics Services: Cell painting and high-content phenomics services providing morphological profiling data for customer cell models or pixlbio's own iPSC-derived systems.
  4. CRISPR Gene Editing Services: Custom CRISPR-Cas9 gene editing services for creating disease models from customer iPSC lines or pixlbio's validated lines. Includes cell line evaluation, sgRNA design, transfection, clone screening, and final validation.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-gopixHep wild-type iPSC-derived hepatocytes
Unit PricingPay-as-you-gopixHep A1ATD disease models
Unit PricingPay-as-you-gopixHep UCD disease models
Unit PricingPay-as-you-gopixStellate iPSC-derived stellate cells
Unit PricingPay-as-you-gopixIO intestinal organoids
Unit PricingPay-as-you-gopixHep/pixStellate Co-Culture Models
Unit PricingPay-as-you-goMASLD CRISPR disease models

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

pixlbio (formerly DefiniGEN) product offering

Product offering

Core offering

pixlbio develops and commercializes human induced pluripotent stem cell (iPSC)-derived cell models and an AI-driven phenomics platform for drug discovery, disease modeling, and preclinical safety assessment. The company sells cryopreserved hepatocytes (pixHep), hepatic stellate cells (pixStellate), intestinal organoids (pixIO), and disease-specific liver models (MASLD, A1ATD, PFIC2, UCD), alongside the pixCellPaint high-content assay, the pixlbio AI Phenomics Platform, and end-to-end pixCellServices contract research.

Product overview

pixlbio is a unified platform combining human iPSC-derived cell models (pixCells portfolio) with AI-driven phenomics for predictive drug discovery and safety assessment. The platform integrates three core product lines: pixHep (iPSC-derived hepatocytes), pixStellate (hepatic stellate cells), and pixIO (intestinal organoids) as the biological foundation; pixCellPaint for high-content cell painting and automated imaging; and pixCellServices for end-to-end research studies with AI analytics. pixCellPaint captures morphological fingerprints via Cell Painting, which pixlbio's AI models analyze to generate predictive insights for drug response, toxicity, and mechanism of action. The SaaS platform delivers structured data, dashboards, and consultative insights. Disease-specific models include MASLD, A1ATD, PFIC2, and UCD variants, alongside custom CRISPR-engineered models. The company was formed in July 2025 through the merger of DefiniGEN (iPSC expertise) and Phenaros (AI phenomics), headquartered in Uppsala, Sweden.

Differentiator

Problem solved

Functional benefit

Brands

  • pixCells: Human iPSC-derived cell models including hepatocytes, stellates, and organoids engineered for physiological relevance, scalability, and stability.
  • pixCellPaint
  • pixCellServices
  • pixIO
  • pixStellate
  • pixHep

Products and services

  • pixHep Human induced pluripotent stem cell (iPSC)-derived hepatocytes supplied as cryopreserved, single-donor cells for drug discovery, hepatotoxicity testing, and liver disease research, sold to pharmaceutical and biotechnology R&D customers.
  • pixStellate Human iPSC-derived hepatic stellate cells for in vitro modeling of liver fibrosis and stellate cell biology, used in combination with pixHep in fibrosis and co-culture applications.
  • pixIO Human iPSC-derived intestinal organoids for gastrointestinal disease modeling, gut-toxicity testing, and pharmacology research, sold to pharma and biotech discovery teams.
  • pixCellPaint High-content cell painting phenomics assay that produces multi-parameter morphological readouts from pixlbio's iPSC-derived cells, enabling quantitative phenotypic profiling for compound screening and target validation.
  • pixCellServices End-to-end drug discovery and disease modeling research services in which pixlbio executes custom iPSC-derived model generation, assay design, pixCellPaint phenotypic screening, and AI-driven data analysis on behalf of pharma, biotech, and academic clients.
  • pixlbio AI Phenomics Platform AI and machine learning platform that analyzes high-content imaging data from pixCellPaint and customer assays, extracting quantitative morphological features and supporting target identification, hit triage, and mechanism-of-action studies.
  • Custom iPSC Disease Models Bespoke iPSC-derived disease models engineered to customer-specified genotypes or indications, including custom gene edits and customer-driven donor backgrounds for proprietary research programs.
  • pixHep MASLD Model Disease-specific iPSC-derived hepatocyte model for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NASH/NAFLD), used to study hepatic steatosis, inflammation, and fibrosis in a human-relevant in vitro setting.
  • pixHep A1ATD Model Disease-specific iPSC-derived hepatocyte model carrying Alpha-1 antitrypsin deficiency (A1ATD) genotype, enabling study of misfolded protein accumulation and liver pathology in A1ATD drug discovery.
  • pixHep PFIC2 Model Disease-specific iPSC-derived hepatocyte model for progressive familial intrahepatic cholestasis type 2 (PFIC2), used to model BSEP transporter dysfunction and cholestasis in vitro for rare liver disease drug discovery.
  • pixHep UCD Model Disease-specific iPSC-derived hepatocyte model for urea cycle disorders (UCD), used to study ammonia detoxification defects and OTC/ASS1/CPS1 pathway dysfunction in vitro.
  • pixHep / pixStellate Co-Culture Co-culture system combining pixHep hepatocytes with pixStellate cells to model hepatocyte-stellate cell cross-talk in liver fibrosis and inflammation studies, sold as an integrated disease modeling product.

Quantifiable outcome

  • Up to ~69% balanced accuracy in leave-one-out compound identification for DILI prediction
  • +3 more outcomes

Companies that use pixlbio (formerly DefiniGEN)

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

pixlbio (formerly DefiniGEN) technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

pixlbio (formerly DefiniGEN) partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered flagship and core.

  • FDA-CDERflagshipStrategic or Co-development Partner · 1 January 2025FDA Center for Drug Evaluation and Research (CDER) co-leads the landmark cross-platform DILI study with the 3Rs Collaborative. Pixl Bio (operating as DefiniGEN at study initiation) was one of eight selected commercial liver MPS platforms contributing to the FDA ISTAND qualification program. Project Letter of Intent accepted into ISTAND in January 2026.
  • 3Rs CollaborativeflagshipStrategic or Co-development Partner · 1 January 20253Rs Collaborative handles project coordination and dissemination for the landmark cross-platform DILI study co-led with FDA-CDER. Pixl Bio is a member of the Microphysiological Systems initiative.
  • NIH-NIEHS/NICEATMcoreStrategic or Co-development Partner · 1 January 2025NIH National Institute of Environmental Health Sciences/NICEATM provides independent data governance including compound selection, blinding, and statistical analysis for the cross-platform DILI study.
  • Critical Path InstitutecoreStrategic or Co-development PartnerContributes context of use and qualification expertise to the FDA-3Rs Collaborative cross-platform DILI study supporting regulatory qualification of liver MPS technologies.
  • AstraZenecacoreStrategic or Co-development PartnerAstraZeneca is a major pharmaceutical customer and represented on the technical leadership committee for the cross-platform DILI study. Also serves as host for the ELRIG Cell-based Screening 2026 conference at their R&D site in Gothenburg.
  • SanoficoreGTM or Marketing PartnerSanofi selected pixlbio as recipient of the iDEA-TECH Awards Program recognizing their high-quality predictive models and expertise in Cell Painting, AI and predictive modelling.
  • Merck & pharmaceutical consultantscoreStrategic or Co-development PartnerProvides technical leadership and compound selection guidance for the FDA-3Rs Collaborative cross-platform DILI study consortium.
  • PhenarosflagshipOthersIn July 2025, DefiniGEN was acquired by Phenaros, forming pixlbio. Phenaros brought complementary capabilities in high-throughput Cell Painting phenomics, AI-driven image analysis, and predictive modeling from their Uppsala founding team.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

pixlbio (formerly DefiniGEN) competitors and assessment

Company assessment

Direct peers

  • InSphero: InSphero provides 3D microtissue and organoid-based assays including liver models for toxicity and disease research, competing directly with pixlbio's pixHep and pixIO products in pharma drug safety and metabolic disease applications.
  • REPROCELL: REPROCELL provides upcyte hepatocytes and iPSC-derived hepatic cells for drug metabolism and toxicology, directly comparable to pixlbio's pixHep cell product line in addressing pharma needs for human-relevant liver models.
  • Emulate: Emulate's Liver-Chip is a leading organ-on-chip platform using primary or iPSC-derived hepatocytes under controlled flow conditions for DILI and drug safety assessment. Direct competitor to pixlbio's pixHep-based offering and fellow FDA-3Rs study participant.
  • MIMETAS: MIMETAS develops organ-on-chip platforms including liver models under the OrganoPlate brand, providing competing MPS solutions to pixlbio for DILI, metabolism, and disease modeling in pharma preclinical pipelines.
  • CN Bio: CN Bio's PhysioMimix liver MPS platform offers single- and multi-organ microphysiological systems for DILI and ADME studies, directly competing with pixlbio in iPSC-derived liver models for pharma preclinical workflows. Both companies participate in the FDA-3Rs Collaborative cross-platform DILI study.
  • Cyprotex (an Evotec company): Cyprotex offers preclinical DILI and ADME services including iPSC-derived hepatocyte assays, overlapping with pixlbio's pixCellServices for pharma customers. As part of Evotec, it represents a larger integrated CRO competitor.

Broad incumbents

  • Lonza: Lonza manufactures primary and iPSC-derived hepatocytes at industrial scale and offers cell therapy and discovery services, providing a broad-incumbent alternative for pharma customers evaluating pixlbio's pixHep cell products.
  • Thermo Fisher Scientific: Thermo Fisher offers Gibco primary hepatocytes, iPSC-derived cell products, and high-content imaging instruments that overlap with pixlbio's pixCells and pixCellPaint offerings, representing a broad life-science tools incumbent.
  • F. Hoffmann-La Roche (Roche): As a top-5 pharma with substantial internal iPSC, organoid, and high-content screening capabilities, Roche represents a broad incumbent that could either be a major pixlbio customer or a long-term competitor through internalization of similar capabilities.

Emerging players

  • Organovo: Organovo focuses on 3D bioprinted human tissues including liver tissue for preclinical research, an emerging alternative to iPSC-derived hepatocyte models like pixHep with partially overlapping pharma use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

pixlbio (formerly DefiniGEN) social profiles

Digital presence

pixlbio (formerly DefiniGEN) compliance and trust

Trust signal

Compliance1 record

pixlbio (formerly DefiniGEN) financial estimates

Financial estimate

Revenue estimate

Valuation estimate

pixlbio (formerly DefiniGEN) leadership team

Management profile

Number of profiles

Profiles3 records

pixlbio (formerly DefiniGEN) funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

pixlbio (formerly DefiniGEN) M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about pixlbio (formerly DefiniGEN)

What does pixlbio (formerly DefiniGEN) do?

pixlbio develops and commercializes human induced pluripotent stem cell (iPSC)-derived cell models and an AI-driven phenomics platform for drug discovery, disease modeling, and preclinical safety assessment. The company sells cryopreserved hepatocytes (pixHep), hepatic stellate cells (pixStellate), intestinal organoids (pixIO), and disease-specific liver models (MASLD, A1ATD, PFIC2, UCD), alongside the pixCellPaint high-content assay, the pixlbio AI Phenomics Platform, and end-to-end pixCellServices contract research.

Is pixlbio (formerly DefiniGEN) a public or private company?

pixlbio (formerly DefiniGEN) is a private company. It is classified as venture growth investor backed and is currently operating.

When was pixlbio (formerly DefiniGEN) founded?

pixlbio (formerly DefiniGEN) was founded in 2012. It employs 11 to 50 people.

Where is pixlbio (formerly DefiniGEN) based?

pixlbio (formerly DefiniGEN) is headquartered in Uppsala, Sweden, in the Europe region.

How does pixlbio (formerly DefiniGEN) make money?

Four revenue lines are on record. iPSC-derived Cell Products are the primary driver. The others are pixCellServices - Custom Studies & Analytics, pixCellPaint - Phenomics Services and CRISPR Gene Editing Services.

Who are pixlbio (formerly DefiniGEN)'s main competitors?

Direct peers on record are InSphero, REPROCELL, Emulate, MIMETAS, CN Bio and Cyprotex (an Evotec company). Broad incumbents are Lonza, Thermo Fisher Scientific and F. Hoffmann-La Roche (Roche). Organovo is listed as an emerging player.

Does pixlbio (formerly DefiniGEN) have an API?

Yes. SaaS platform with API-based access enabling partners to track experiments in real-time and run in-silico phenomic predictions through secure, API-based access.

What industry is pixlbio (formerly DefiniGEN) in?

pixlbio (formerly DefiniGEN)'s product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals